)
Albert Gianchetti
President & CEO
Nuevocor Therapeutics
Al Gianchetti joins Nuevocor with more than 30 years of drug development and commercialization experience, with a specialized focus on cardiovascular and metabolic therapies. For the last 10 years, he served as President and CEO of XyloCor Therapeutics, where he oversaw major clinical milestones, secured significant Series B investment and advanced its gene therapy programs for patients with cardiovascular disease into late- stage clinical development. Prior to this role, Al Gianchetti held executive positions at GSK and leadership roles at small biotech and specialty pharma. He brings extensive experience in biotech leadership, fundraising and business development, commercial strategy and R&D.
Sessions
-
24-Jun-2026Theater 4Nuevocor Therapeutics
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}